Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 10.4% year on year to $257.7 million. Guidance for next quarter’s revenue was better than expected at $261.5 million at the midpoint, 1.4% above analysts’ estimates. Its non-GAAP profit of $0.81 per share was 4.3% above analysts’ consensus estimates.